Recent advances in antifungal chemotherapy

Ellis, 2002, Invasive fungal infections: evolving challenges for diagnosis and therapeutics, Mol Immunol, 38, 947, 10.1016/S0161-5890(02)00022-6 Edmond, 1999, Nosocomial bloodstream infections in United States hospitals: a three-year analysis, Clin Infect Dis, 29, 239, 10.1086/520192 Roden, 2005, Epidemiology and outcome of zygomycosis: a review of 929 reported cases, Clin Infect Dis, 41, 634, 10.1086/432579 Ostrosky-Zeichner, 2003, Amphotericin B: time for a new ‘gold standard’, Clin Infect Dis, 37, 415, 10.1086/376634 Espinel-Ingroff, 2001, In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature, Mycopathologia, 150, 101, 10.1023/A:1010954803886 Theuretzbacher, 2006, Pharmacokinetic/pharmacodynamic profile of voriconazole, Clin Pharmacokinet, 45, 649, 10.2165/00003088-200645070-00002 Courtney, 2003, Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults, Antimicrob Agents Chemother, 47, 2788, 10.1128/AAC.47.9.2788-2795.2003 Stone, 2002, Single- and multiple-dose pharmacokinetics of caspofungin in healthy men, Antimicrob Agents Chemother, 46, 739, 10.1128/AAC.46.3.739-745.2002 Herbert, 2005, Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction, J Clin Pharmacol, 45, 1145, 10.1177/0091270005279580 Dowell, 2004, Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal, J Clin Pharmacol, 44, 590, 10.1177/0091270004265644 Pearson, 2003, Voriconazole: a new triazole antifungal agent, Ann Pharmacother, 37, 420, 10.1345/aph.1C261 Mouas, 2005, Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases, Clin Infect Dis, 40, 1141, 10.1086/428734 Studahl, 2003, Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery, Acta Paediatr, 92, 980, 10.1111/j.1651-2227.2003.tb00636.x Breit, 2005, Management of endogenous fungal endophthalmitis with voriconazole and caspofungin, Am J Ophthalmol, 139, 135, 10.1016/j.ajo.2004.08.077 Nesky, 2000, Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis, Clin Infect Dis, 31, 673, 10.1086/314042 Schwarz, 1997, Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia, Br J Haematol, 98, 1052 Kullberg, 2005, Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial, Lancet, 366, 1435, 10.1016/S0140-6736(05)67490-9 Ostrosky-Zeichner, 2003, Voriconazole salvage treatment of invasive candidiasis, Eur J Clin Microbiol Infect Dis, 22, 651, 10.1007/s10096-003-1014-3 Ally, 2001, A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients, Clin Infect Dis, 33, 1447, 10.1086/322653 Perfect, 2003, Voriconazole treatment for less common, emerging, or refractory fungal infections, Clin Infect Dis, 36, 1122, 10.1086/374557 Herbrecht, 2002, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med, 347, 408, 10.1056/NEJMoa020191 Denning, 2002, Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis, Clin Infect Dis, 34, 563, 10.1086/324620 Walsh, 2002, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever, N Engl J Med, 346, 225, 10.1056/NEJM200201243460403 Steinbach, 2004, Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases, Clin Infect Dis, 39, 192, 10.1086/421950 Hoffman, 2002, Review of the safety and efficacy of voriconazole, Expert Opin Investig Drugs, 11, 409, 10.1517/13543784.11.3.409 Imhof, 2004, Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole, Clin Infect Dis, 39, 743, 10.1086/423274 Law, 1997, Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp., Antimicrob Agents Chemother, 41, 2310, 10.1128/AAC.41.10.2310 Galgiani, 1997, In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts, Antimicrob Agents Chemother, 41, 180, 10.1128/AAC.41.1.180 Oakley, 1997, In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp., Antimicrob Agents Chemother, 41, 1124, 10.1128/AAC.41.5.1124 Marco, 1998, In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi, Mycopathologia, 141, 73, 10.1023/A:1006970503053 Gonzalez, 2005, In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi, Med Mycol, 43, 281, 10.1080/13693780500088416 Courtney, 2004, Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men, Antimicrob Agents Chemother, 48, 804, 10.1128/AAC.48.3.804-808.2004 Cornely, 2007, Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia, N Engl J Med, 356, 348, 10.1056/NEJMoa061094 Ullmann, 2007, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N Engl J Med, 356, 335, 10.1056/NEJMoa061098 Vazquez, 2006, A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS, Clin Infect Dis, 42, 1179, 10.1086/501457 Ullmann, 2006, Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection, Antimicrob Agents Chemother, 50, 658, 10.1128/AAC.50.2.658-666.2006 Walsh, 2007, Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial, Clin Infect Dis, 44, 2, 10.1086/508774 Greenberg, 2006, Posaconazole as salvage therapy for zygomycosis, Antimicrob Agents Chemother, 50, 126, 10.1128/AAC.50.1.126-133.2006 Van Burik, 2006, Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases, Clin Infect Dis, 42, e61, 10.1086/500212 Raad, 2006, Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions, Clin Infect Dis, 42, 1398, 10.1086/503425 Pitisuttithum, 2005, Activity of posaconazole in the treatment of central nervous system fungal infections, J Antimicrob Chemother, 56, 745, 10.1093/jac/dki288 Anstead, 2005, Refractory coccidioidomycosis treated with posaconazole, Clin Infect Dis, 40, 1770, 10.1086/430303 Raad, 2006, Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections, Clin Infect Dis, 42, 1726, 10.1086/504328 Wexler, 2004, Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study, Eur J Pharm Sci, 21, 645, 10.1016/j.ejps.2004.01.005 Yamazumi, 2000, In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans, Antimicrob Agents Chemother, 44, 2883, 10.1128/AAC.44.10.2883-2886.2000 Pfaller, 2002, In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp., Antimicrob Agents Chemother, 46, 1723, 10.1128/AAC.46.6.1723-1727.2002 Cuenca-Estrella, 2005, In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi, Antimicrob Agents Chemother, 49, 5136, 10.1128/AAC.49.12.5136-5138.2005 Beale, 2001, Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis Nyfeler, 1974, Metabolics of microorganisms. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components, Helv Chim Acta, 57, 2459, 10.1002/hlca.19740570818 Onishi, 2000, Discovery of novel antifungal (1,3)-β-d-glucan synthase inhibitors, Antimicrob Agents Chemother, 44, 368, 10.1128/AAC.44.2.368-377.2000 Vazquez, 1997, In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species, Antimicrob Agents Chemother, 41, 1612, 10.1128/AAC.41.7.1612 Barchiesi, 1999, In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species, Eur J Clin Microbiol Infect Dis, 18, 302, 10.1007/s100960050283 Kartsonis, 2005, Caspofungin susceptibility testing of isolates from patients with esophageal or invasive candidiasis: relationship of MIC to treatment outcome, Antimicrob Agents Chemother, 49, 3616, 10.1128/AAC.49.9.3616-3623.2005 Park, 2005, Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates, Antimicrob Agents Chemother, 49, 3264, 10.1128/AAC.49.8.3264-3273.2005 Colombo, 2003, Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis, Eur J Clin Microbiol Infect Dis, 22, 470, 10.1007/s10096-003-0973-8 Moudgal, 2005, Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis, Antimicrob Agents Chemother, 49, 767, 10.1128/AAC.49.2.767-769.2005 Hernandez, 2004, Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis, Antimicrob Agents Chemother, 48, 1382, 10.1128/AAC.48.4.1382-1383.2004 Krogh-Madsen, 2006, Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient, Clin Infect Dis, 42, 938, 10.1086/500939 Pfaller, 1998, In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi, Diagn Microbiol Infect Dis, 30, 251, 10.1016/S0732-8893(97)00246-0 Abruzzo, 1997, Evaluation of echinocandin antifungal MK-0991 (l-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis, Antimicrob Agents Chemother, 41, 2333, 10.1128/AAC.41.11.2333 Villanueva, 2002, A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis, Am J Med, 113, 294, 10.1016/S0002-9343(02)01191-9 Arathoon, 2002, Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis, Antimicrob Agents Chemother, 46, 451, 10.1128/AAC.46.2.451-457.2002 Villanueva, 2001, A randomized double-blind study of caspofungin versus amphotericin B for the treatment of candidal esophagitis, Clin Infect Dis, 33, 1529, 10.1086/323401 Mora-Duarte, 2002, Comparison of caspofungin and amphotericin B for invasive candidiasis, N Engl J Med, 347, 2020, 10.1056/NEJMoa021585 Maertens, 2004, Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patient refractory to or intolerant of conventional antifungal therapy, Clin Infect Dis, 39, 1563, 10.1086/423381 Kartsonis, 2005, Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study, J Infect, 50, 196, 10.1016/j.jinf.2004.05.011 Walsh, 2004, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med, 351, 1391, 10.1056/NEJMoa040446 Merck & Co. Cancidas prescribing information. Whitehouse Station, NJ: Merck; 2004. Stone, 2004, Potential for interactions between caspofungin and nelfinavir or rifampin, Antimicrob Agents Chemother, 48, 4306, 10.1128/AAC.48.11.4306-4314.2004 Caspofungin (Cancidas) for aspergillosis. Med Lett Drugs Ther 2001; 43:58. Marr, 2004, Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A, Transpl Infect Dis, 6, 110, 10.1111/j.1399-3062.2004.00065.x Kohno, 2004, A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan, Scand J Infect Dis, 36, 372, 10.1080/00365540410020406 de Wet, 2005, A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis, Aliment Pharmacol Ther, 21, 899, 10.1111/j.1365-2036.2005.02427.x Pettengell, 2004, Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent, Aliment Pharmacol Ther, 20, 475, 10.1111/j.1365-2036.2004.02083.x de Wet, 2004, A randomized, double-blind, parallel-group, dose–response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients, Clin Infect Dis, 39, 842, 10.1086/423377 Ostrosky-Zeichner, 2005, International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia, Eur J Clin Microbiol Infect Dis, 24, 654, 10.1007/s10096-005-0024-8 van Burik, 2004, Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation, Clin Infect Dis, 39, 1407, 10.1086/422312 Ota, 2004, Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study, Int J Hematol, 79, 390, 10.1532/IJH97.03163 Yokote, 2004, Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy, Ann Hematol, 88, 64, 10.1007/s00277-003-0736-8 Singer, 2003, Successful treatment of invasive aspergillosis in two patients with acute myeloid leukaemia, J Pediatr Hematol Oncol, 25, 252, 10.1097/00043426-200303000-00014 Hebert, 2005, Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers, J Clin Pharmacol, 45, 954, 10.1177/0091270005278601 Astellas, 2005 Arévalo, 2003, Antifungal activity of the echinocandin anidulafungin (VER002,LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method, J Antimicrob Chemother, 51, 163, 10.1093/jac/dkg018 Zhanel, 1997, In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species, Antimicrob Agents Chemother, 41, 863, 10.1128/AAC.41.4.863 Efficacy of anidulafungin (ANID) in patients (pts) with azole-refractory mucosal candidiasis (ARMC). In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 30 October–2 November 2004; Washington, DC. Washington, DC: ASM Press; 2004 [abstract M-1038]. Phase II, randomized, open-label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17–20 September 2000; Toronto, Ontario. Washington, DC: ASM Press; 2000. [abstract 1106]. Krause, 2004, A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis, Clin Infect Dis, 39, 770, 10.1086/423378 Krause, 2004, Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia, Antimicrob Agents Chemother, 48, 2021, 10.1128/AAC.48.6.2021-2024.2004 Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis (C/IC). In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16-19 December 2005; Washington, DC. Washington, DC: ASM Press; 2005. [abstract M-718]. Trissel, 2005, Compatibility of anidulafungin with other drugs during simulated Y-site administration, Am J Health Syst Pharm, 62, 834, 10.1093/ajhp/62.8.834 Fohrer, 2006, Antifungal combination treatment: a future perspective, Int J Antimicrob Agents, 27, 25, 10.1016/j.ijantimicag.2006.03.016 Chamilos, 2006, The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine, Curr Opin Infect Dis, 19, 380, 10.1097/01.qco.0000235166.16421.e5